Search research articles
Contact Us
Filters
Showing results (91-100 of 139) with videos related to
Page
of 14
Sort By:
Biomedicines
|
December 15, 2020
Modulating the Heat Sensitivity of Prostate Cancer Cell Lines In Vitro: A New Impact for Focal Therapies
Oliver Hahn, Franziska M Heining, Jörn Janzen, et al.
Langenbeck'S Archives of Surgery
|
December 25, 2016
Effective downsizing but enhanced intratumoral heterogeneity following neoadjuvant sorafenib in patients with non-metastatic renal cell carcinoma
Gencay Hatiboglu, Markus Hohenfellner, Aysenur Arslan, et al.
Frontiers in Oncology
|
June 20, 2025
Digital spatial profiling identifies phospho-JNK as a biomarker for early risk stratification of aggressive prostate cancer
Samaneh Eickelschulte, Adam Kaczorowski, Florian Janke, et al.
The Journal of Pathology
|
July 17, 2015
PBRM1 (BAF180) protein is functionally regulated by p53-induced protein degradation in renal cell carcinomas
Stephan Macher-Goeppinger, Martina Keith, Katrin E Tagscherer, et al.
Cancers
|
April 30, 2021
Efficacy and Safety of Checkpoint Inhibitor Treatment in Patients with Advanced Renal or Urothelial Cell Carcinoma and Concomitant Chronic Kidney Disease: A Retrospective Cohort Study
Florian Seydel, Susanne Delecluse, Martin Zeier, et al.
Oncotarget
|
November 2, 2017
Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy
Steffen Dietz, Holger Sültmann, YueJun Du, et al.
Cancer Research
|
December 24, 2009
Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells
Sebastian Bauer, Joshua A Parry, Thomas Mühlenberg, et al.
International Journal of Cancer
|
July 20, 2016
Targeting DDR2 in head and neck squamous cell carcinoma with dasatinib
Anne von Mässenhausen, Christine Sanders, Johannes Brägelmann, et al.
Urologic Oncology
|
June 12, 2018
FGF-2 is a driving force for chromosomal instability and a stromal factor associated with adverse clinico-pathological features in prostate cancer
Carine Pecqueux, Aysenur Arslan, Martina Heller, et al.
Biomarker Research
|
April 4, 2023
Co-expression and clinical utility of AR-FL and AR splice variants AR-V3, AR-V7 and AR-V9 in prostate cancer
Neele Wüstmann, Konstantin Egon Seifert, Verena Humberg, et al.
Page
of 14
Search research articles
Search
Showing results (91-100 of 139) with videos related to
Sort By:
Page
of 14
Biomedicines
|
December 15, 2020
Modulating the Heat Sensitivity of Prostate Cancer Cell Lines In Vitro: A New Impact for Focal Therapies
Oliver Hahn, Franziska M Heining, Jörn Janzen, et al.
Langenbeck'S Archives of Surgery
|
December 25, 2016
Effective downsizing but enhanced intratumoral heterogeneity following neoadjuvant sorafenib in patients with non-metastatic renal cell carcinoma
Gencay Hatiboglu, Markus Hohenfellner, Aysenur Arslan, et al.
Frontiers in Oncology
|
June 20, 2025
Digital spatial profiling identifies phospho-JNK as a biomarker for early risk stratification of aggressive prostate cancer
Samaneh Eickelschulte, Adam Kaczorowski, Florian Janke, et al.
The Journal of Pathology
|
July 17, 2015
PBRM1 (BAF180) protein is functionally regulated by p53-induced protein degradation in renal cell carcinomas
Stephan Macher-Goeppinger, Martina Keith, Katrin E Tagscherer, et al.
Cancers
|
April 30, 2021
Efficacy and Safety of Checkpoint Inhibitor Treatment in Patients with Advanced Renal or Urothelial Cell Carcinoma and Concomitant Chronic Kidney Disease: A Retrospective Cohort Study
Florian Seydel, Susanne Delecluse, Martin Zeier, et al.
Oncotarget
|
November 2, 2017
Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy
Steffen Dietz, Holger Sültmann, YueJun Du, et al.
Cancer Research
|
December 24, 2009
Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells
Sebastian Bauer, Joshua A Parry, Thomas Mühlenberg, et al.
International Journal of Cancer
|
July 20, 2016
Targeting DDR2 in head and neck squamous cell carcinoma with dasatinib
Anne von Mässenhausen, Christine Sanders, Johannes Brägelmann, et al.
Urologic Oncology
|
June 12, 2018
FGF-2 is a driving force for chromosomal instability and a stromal factor associated with adverse clinico-pathological features in prostate cancer
Carine Pecqueux, Aysenur Arslan, Martina Heller, et al.
Biomarker Research
|
April 4, 2023
Co-expression and clinical utility of AR-FL and AR splice variants AR-V3, AR-V7 and AR-V9 in prostate cancer
Neele Wüstmann, Konstantin Egon Seifert, Verena Humberg, et al.
Page
of 14